<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COMBIVIR- lamivudine and zidovudineÂ tablet, film coatedÂ </strong><br>ViiV Healthcare Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use COMBIVIR safely and effectively. See full prescribing information for COMBIVIR.<br>Â <br>COMBIVIR (lamivudine and zidovudine) tablets<br>Initial U.S. Approval: 1997</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Hematologic Toxicity</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been associated with the use of zidovudine, a component of COMBIVIR (<a href="#_5.1_Hemotologic_Toxicity/Bone">5.1</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (<a href="#ID_cb66871a-61fe-405c-a388-299601f71f12">5.2</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#_5.3_Lactic_Acidosis/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (<a href="#_5.4_Patients_With">5.4</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<table width="100%">
<col width="43%">
<col width="11%">
<tbody class="Headless"><tr>
<td valign="top"><p class="Highlighta">Warnings and Precautions (<a href="#i4i_warnings_precautions_id_5080500e-260e-49e3-86f7-55f32f2d4d04">5</a>) </p></td>
<td align="right" valign="top"><p class="Highlighta">09/2015 </p></td>
</tr></tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Hematologic Toxicity</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been associated with the use of zidovudine, a component of COMBIVIR (<a href="#_5.1_Hemotologic_Toxicity/Bone">5.1</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (<a href="#ID_cb66871a-61fe-405c-a388-299601f71f12">5.2</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#_5.3_Lactic_Acidosis/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (<a href="#_5.4_Patients_With">5.4</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">COMBIVIR, a combination of 2Â nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#i4i_indications_id_9157e013-d737-4490-a3cd-66413bbc0270">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Adults and Adolescents weighing greater than or equal to 30Â kg: 1Â tablet orally twice daily. <a href="#i4i_section_id_325f6e97-1ea6-428b-900a-efe3a37396f3">(</a><a href="#i4i_section_id_325f6e97-1ea6-428b-900a-efe3a37396f3">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Pediatrics weighing greater than or equal to 30Â kg: 1Â tablet orally twice daily. (<a href="#i4i_section_id_5ed9f689-eca7-488d-a420-1f62459ef18b">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>Because COMBIVIR is a fixedâ€‘dose tablet and cannot be dose adjusted, COMBIVIR is not recommended in patients requiring dosage adjustment or with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or experiencing doseâ€‘limiting adverse reactions. (<a href="#i4i_section_id_1dd7e435-d212-417e-891e-44da47f94ec6">2.3</a>, <a href="#i4i_contraindications_id_f74d4c49-160b-417a-b916-e57da6d0db06">4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: Scored 150 mg lamivudine and 300 mg zidovudine (<a href="#i4i_dosage_form_strength_id_d55d40f0-3e6f-48dc-8420-6f8a608f8d26">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">COMBIVIR is contraindicated in patients with a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to lamivudine or zidovudine. (<a href="#i4i_contraindications_id_f74d4c49-160b-417a-b916-e57da6d0db06">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>COMBIVIR should not be administered with other lamivudine- or zidovudineâ€‘containing products or emtricitabineâ€‘containing products. (<a href="#_5.5_Use_With">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue COMBIVIR as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (<a href="#_5.6_Use_With">5.6</a>)</dd>
<dt>â€¢</dt>
<dd>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised. (<a href="#_5.6_Use_With">5.6</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>: Use with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or other significant risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Discontinue treatment as clinically appropriate. (<a href="#_5.7_Pancreatitis">5.7</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy (<a href="#_5.8_Immune_Reconstitution">5.8</a>, <a href="#_5.9_Fat_Redistribution">5.9</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, nasal signs and symptoms, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. (<a href="#i4i_section_id_a2acd8ab-c828-4c6d-819f-63785ea8c83c">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <a href="#_Ref">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Agents antagonistic with zidovudine: Concomitant use should be avoided (<a href="#i4i_section_id_c8f7b5cc-612b-40fd-88ad-2ec1e11ba8dd">7.1</a>)) </dd>
<dt>â€¢</dt>
<dd>Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (<a href="#i4i_section_id_c8f7b5cc-612b-40fd-88ad-2ec1e11ba8dd">7.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Lactation: Breastfeeding not recommended. (<a href="#i4i_nursing_mothers_id_d9e6f009-0d43-4ff1-bf19-d5479bff3f9b">8.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosage for Adults and Adolescents </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosage for Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Not Recommended Due to Lack of Dosage Adjustment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hematologic Toxicity/Bone Marrow Suppression </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>  </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Related Products that are Not Recommended </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use with Interferon- and Ribavirin-based Regimens </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>  </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Fat Redistribution  </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Zidovudine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with Impaired Hepatic Function</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Prevention of Maternal-Fetal HIV-1 Transmission</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_b2c19d4f-e837-40e8-9c51-49538ac7ca8d"></a><a name="section-1"></a><p></p>
<h1>WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<p class="First"><span class="Bold"><span class="Underline">Hematologic Toxicity</span></span></p>
<p><span class="Bold">Zidovudine, a component of COMBIVIR<span class="Sup">Â®</span> (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1) disease <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span></span></p>
<p><span class="Bold">Prolonged use of zidovudine has been associated with symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</span></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals. Discontinue COMBIVIR if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</span></p>
<p><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span></p>
<p><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9157e013-d737-4490-a3cd-66413bbc0270"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">COMBIVIR, a combination of 2Â nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIVâ€‘1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d00470dd-e50c-4159-82b8-758afbeabd0a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_325f6e97-1ea6-428b-900a-efe3a37396f3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosage for Adults and Adolescents </h2>
<p class="First">The recommended dosage of COMBIVIR in HIVâ€‘1â€‘infected adults and adolescents weighing greater than or equal to 30Â kg is 1Â tablet (containing 150Â mg of lamivudine and 300Â mg of zidovudine) taken orally twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ed9f689-eca7-488d-a420-1f62459ef18b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosage for Pediatric Patients</h2>
<p class="First">The recommended dosage of scored COMBIVIR tablets for pediatric patients who weigh greater than or equal to 30Â kg and for whom a solid oral dosage form is appropriate is 1Â tablet administered orally twice daily.</p>
<p>Before prescribing COMBIVIR tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow a COMBIVIR tablet, the liquid oral formulations should be prescribed: EPIVIR<span class="Sup">Â®</span> (lamivudine) oral solution and RETROVIR<span class="Sup">Â®</span>Â (zidovudine) syrup.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1dd7e435-d212-417e-891e-44da47f94ec6"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Not Recommended Due to Lack of Dosage Adjustment</h2>
<p class="First">Because COMBIVIR is a fixedâ€‘dose tablet and cannot be dose adjusted, COMBIVIR is not recommended for:</p>
<dl>
<dt>â€¢</dt>
<dd>pediatric patients weighing less than 30Â kg <span class="Italics">[see Use in Specific Populations (8.4)]</span>.</dd>
<dt>â€¢</dt>
<dd>patients with creatinine clearance less than 50Â mL per minute <span class="Italics">[see Use in Specific Populations (8.6)]</span>.</dd>
<dt>â€¢</dt>
<dd>patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations (8.7)]</span>.</dd>
<dt>â€¢</dt>
<dd>patients experiencing doseâ€‘limiting adverse reactions.</dd>
</dl>
<p>Liquid and solid oral formulations of the individual components of COMBIVIR are available for these populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_d55d40f0-3e6f-48dc-8420-6f8a608f8d26"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">COMBIVIR tablets contain 150Â mg of lamivudine and 300Â mg of zidovudine. The tablets are white, scored, film-coated, modified capsule-shaped tablets, debossed on both tablet faces, such that when broken in half, the full â€œGX FC3â€? code is present on both halves of the tablet (â€œGXâ€? on one face and â€œFC3â€? on the opposite face of the tablet).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f74d4c49-160b-417a-b916-e57da6d0db06"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">COMBIVIR is contraindicated in patients with a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to lamivudine or zidovudine.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_5080500e-260e-49e3-86f7-55f32f2d4d04"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2dabfbe-e1f5-4c52-b3d1-69f2559f1efb"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hematologic Toxicity/Bone Marrow Suppression </h2>
<p class="First">Zidovudine, a component of COMBIVIR, has been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced HIV-1 disease. COMBIVIR should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000Â cells per mm<span class="Sup">3</span> or hemoglobin less than 9.5Â grams per dL <span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
<p>Frequent blood counts are strongly recommended in patients with advanced HIV-1 disease who are treated with COMBIVIR. Periodic blood counts are recommended for other HIV-1-infected patients. If <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops, dosage interruption may be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cb66871a-61fe-405c-a388-299601f71f12"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>  </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, with pathological changes similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine, and therefore may occur with therapy with COMBIVIR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_963a372d-bf12-4536-ab46-724f424d06d6"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis </h2>
<p class="First" style="border-left:1px solid;"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. <span class="XmChange">See full prescribing information for EPIVIR (lamivudine) and RETROVIR (zidovudine). </span>Treatment with COMBIVIR should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_62ae184e-37aa-4a29-9c35-de21044543ca"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </h2>
<p class="First"><span class="Underline">Posttreatment Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></span></p>
<p style="border-left:1px solid;">Clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of lamivudine.<span class="XmChange"> See full prescribing information for EPIVIR (lamivudine). </span>Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.</p>
<p><span class="Underline">Emergence of Lamivudine-resistant HBV</span></p>
<p style="border-left:1px solid;">Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitisÂ B in subjects dually infected with HIVâ€‘1 and HBV. Emergence of hepatitisÂ B virus variants associated with resistance to lamivudine has been reported in HIV-1â€‘infected subjects who have received lamivudineâ€‘containing antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with hepatitisÂ B virus.<span class="XmChange"> See full prescribing information for EPIVIR (lamivudine).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3bbe91f6-ce29-4861-9997-fd1bb293dc64"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Related Products that are Not Recommended </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">COMBIVIR is a fixed-dose combination of 2 nucleoside analogue reverse transcriptase inhibitors (lamivudine and zidovudine). Concomitant administration of COMBIVIR with other products containing lamivudine or zidovudine is not recommended.</span> In addition, do not administer COMBIVIR in combination with products containing emtricitabine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5d45acfb-89bc-4087-b319-860cd17199ff"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use with Interferon- and Ribavirin-based Regimens </h2>
<p class="First" style="border-left:1px solid;">Patients receiving interferon alfa with or without ribavirin and COMBIVIR should be closely monitored for treatmentâ€‘associated toxicities, especially hepatic decompensation, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="XmChange">See full prescribing information for EPIVIR (lamivudine) and RETROVIR (zidovudine).</span> Discontinuation of COMBIVIR should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6) (see full prescribing information for interferon and ribavirin).</p>
<p>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and COMBIVIR is not advised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eeb98084-9c09-4759-b455-9f9af2191389"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>  </h2>
<p class="First">COMBIVIR should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or other significant risk factors for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Treatment with COMBIVIR should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur <span class="Italics">[see Adverse Reactions (6.1)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7ebeeb79-4ac0-456d-8034-f8d1abb9df64"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including COMBIVIR. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b2a5080d-2341-45ad-92d1-aa7760ca528f"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Fat Redistribution  </h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_697a1a50-6b29-4b99-8eb2-aaf1d14c2c09"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd>Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)].</span>
</dd>
<dt>â€¢</dt>
<dd>Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)].</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3)].</span>
</dd>
<dt>â€¢</dt>
<dd>Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.4)].</span>
</dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="Italics">[see Warnings and Precautions (5.6)].</span>
</dd>
<dt>â€¢</dt>
<dd>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine <span class="Italics">[see Warnings and Precautions (5.6)].</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <span class="Italics">[see Warnings and Precautions (5.7)].</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</dd>
<dt>â€¢</dt>
<dd>Fat redistribution <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2acd8ab-c828-4c6d-819f-63785ea8c83c"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p><span class="Underline">Lamivudine plus Zidovudine Administered as Separate Formulations</span></p>
<p>In 4Â randomized, controlled trials of EPIVIR 300Â mg per day plus RETROVIR 600Â mg per day, the following selected adverse reactions and laboratory abnormalities were observed (see Tables 1 and 2).</p>
<a name="_Refid_8812c922-7046-4bbc-a800-98fdb8d60"></a><table width="100%">
<caption><span>Table 1. Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in 4 Controlled Clinical Trials with EPIVIR 300Â mg per day and RETROVIR 600Â mg per day</span></caption>
<col width="55%">
<col width="45%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR plus RETROVIR</span></p>
<p><span class="Bold">(nÂ =Â 251)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Body as a whole</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">35%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> &amp; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">27%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Digestive</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">33%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">18%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">13%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Nervous system</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> &amp; other <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Nasal signs &amp; symptoms</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">20%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">18%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Skin</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Musculoskeletal</span></p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 9 of the 2,613Â adult subjects (0.3%) who received EPIVIR in controlled clinical trials<span class="Italics"> [see Warnings and Precautions (5.7)]</span>.</p>
<p>Selected laboratory abnormalities observed during therapy are listed in TableÂ 2.</p>
<a name="_Refid_6f8c72f9-50bb-46e6-85f0-fc5011fff"></a><table width="100%">
<caption><span>Table 2. Frequencies of Selected Laboratory Abnormalities among Adults in 4 Controlled Clinical Trials of EPIVIR 300Â mg per day plus RETROVIR 600Â mg per day<span class="Sup">a</span></span></caption>
<col width="60%">
<col width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Test</span></p>
<p><span class="Bold">(Abnormal Level)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR plus RETROVIR</span></p>
<p><span class="Bold">%Â (n)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC&lt;750/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">7.2% (237)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb&lt;8.0Â g/dL)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2.9% (241)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (platelets&lt;50,000/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">0.4% (240)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">ALT (&gt;5.0 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3.7% (241)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">AST (&gt;5.0 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">1.7% (241)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Bilirubin (&gt;2.5 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">0.8% (241)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Amylase (&gt;2.0 x ULN)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.2% (72)</p></td>
</tr>
<tr><td class="Lrule Rrule" colspan="2" valign="top"><p class="First">ULNÂ =Â Upper limit of normal.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="2" valign="top"><p class="First">ANCÂ =Â Absolute neutrophil count.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="2" valign="top"><p class="First">nÂ =Â Number of subjects assessed.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First"><span class="Sup">a</span> Frequencies of these laboratory abnormalities were higher in subjects with mild laboratory abnormalities at baseline.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf39b8b7-cdca-4c1e-9462-7e6a92177c87"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Underline">Body as a Whole</span></p>
<p>Redistribution/accumulation of body fat <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</p>
<p><span class="Underline">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>.</p>
<p><span class="Underline">Endocrine and Metabolic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Underline">Gastrointestinal</span></p>
<p>Oral mucosal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><span class="Underline">General</span></p>
<p><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Underline">Hemic and Lymphatic</span></p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Underline">Hepatic and Pancreatic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, posttreatment exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3), (5.4), (5.7)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p>Sensitization reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Underline">Musculoskeletal</span></p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, CPK elevation, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Underline">Nervous</span></p>
<p><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Underline">Respiratory</span></p>
<p>Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
<p><span class="Underline">Skin</span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_26e1e87d-669b-487c-a498-9690f34d90e6"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8f7b5cc-612b-40fd-88ad-2ec1e11ba8dd"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Zidovudine</h2>
<p class="First"><span class="Underline">Agents Antagonistic with Zidovudine</span></p>
<p>Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro:</p>
<dl>
<dt>â€¢</dt>
<dd>Stavudine</dd>
<dt>â€¢</dt>
<dd>Doxorubicine</dd>
<dt>â€¢</dt>
<dd>Nucleoside analogues e.g., ribavirin</dd>
</dl>
<p><span class="Underline">Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</span></p>
<p>Coadministration with the following drugs may increase the hematologic toxicity of zidovudine:</p>
<dl>
<dt>â€¢</dt>
<dd>Ganciclovir</dd>
<dt>â€¢</dt>
<dd>Interferon alfa</dd>
<dt>â€¢</dt>
<dd>Ribavirin</dd>
<dt>â€¢</dt>
<dd>Other bone marrow suppressive or cytotoxic agents</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_24eb4ab2-0bf0-42c7-823d-971176ceea39"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5c5703f6-6060-4ce9-aac8-32d3fa0de1f2"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p><span class="Underline">Pregnancy Exposure Registry</span></p>
<p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to COMBIVIR during pregnancy. Physicians are encouraged to register patients by calling the Antiretroviral Pregnancy Registry at 1-800-258-4263.</p>
<p><span class="Underline">Fetal Risk Summary</span></p>
<p>There are no adequate and well-controlled trials of COMBIVIR (lamivudine and zidovudine) in pregnant women. Clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the fetus. Animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (zidovudine), and increased embryolethality (lamivudine). COMBIVIR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Underline">Clinical Considerations</span></p>
<p>Treatment of HIV during pregnancy optimizes the health of both mother and fetus. Clinical trial data reviewed by FDA demonstrate that maternal zidovudine treatment significantly reduces vertical transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the fetus <span class="Italics">[see Clinical Studies (14.2)]</span>. Published data suggest that combination antiretroviral regimens may reduce the rate of vertical transmission even further.</p>
<p>Pharmacokinetics of lamivudine and zidovudine in pregnant women are similar to the pharmacokinetics in non-pregnant women. No dose adjustments are needed during pregnancy.</p>
<p>In a clinical trial, adverse events among HIV-1-infected women were not different among untreated women and women treated with zidovudine. It is not known whether risks of adverse events associated with lamivudine are altered in pregnant women compared with other HIV-1-infected patients (see Human data below).</p>
<p><span class="Underline">Data</span></p>
<p><span class="Italics">Human Data: Lamivudine: </span>Lamivudine pharmacokinetics were studied in pregnant women during 2Â clinical trials conducted in South Africa. The trial assessed pharmacokinetics in: 16Â women at 36Â weeks gestation using 150Â mg lamivudine twice daily with zidovudine, 10Â women at 38Â weeks gestation using 150Â mg lamivudine twice daily with zidovudine, and 10Â women at 38Â weeks gestation using lamivudine 300Â mg twice daily without other antiretrovirals. Lamivudine pharmacokinetics in pregnant women were similar to those seen in non-pregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples.</p>
<p><span class="Italics">Zidovudine: </span>In a randomized, double-blind, placebo-controlled trial was conducted in HIV-1-infected pregnant women to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission. Zidovudine treatment during pregnancy reduced the rate of maternal-fetal HIV-1 transmission from 24.9% for infants born to placebo-treated mothers to 7.8% for infants born to mothers treated with zidovudine. There were no differences in pregnancy-related adverse events between the treatment groups. Congenital abnormalities occurred with similar frequency between neonates born to mothers who received zidovudine and neonates born to mothers who received placebo. The observed abnormalities included problems in embryogenesis (prior to 14 weeks) or were recognized on ultrasound before or immediately after initiation of trial drug <span class="Italics">[see Clinical Studies (14.2)]</span>.</p>
<p>Zidovudine pharmacokinetics were studied in a PhaseÂ 1 trial of 8Â women during the last trimester of pregnancy. As pregnancy progressed, there was no evidence of drug accumulation. The pharmacokinetics of zidovudine were similar to that of non-pregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery.</p>
<p><span class="Italics">Animal Data: Lamivudine: </span>Animal reproduction studies performed at oral doses up to 130 and 60Â times the adult dose in rats and rabbits, respectively, revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine. Increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. However, there was no indication of this effect in rats at exposure levels up to 35Â times those in humans. Based on animal studies, lamivudine crosses the placenta and is transferred to the fetus <span class="Italics">[see Nonclinical Toxicology (13.2)].</span></p>
<p><span class="Italics">Zidovudine: </span>Increased fetal resorptions occurred in pregnant rats and rabbits treated with doses of zidovudine that produced drug plasma concentrations 66 to 226Â times (rats) and 12Â to 87Â times (rabbits) the mean steady-state peak human plasma concentration following a single 100-mg dose of zidovudine. There were no other reported developmental anomalies. In another developmental toxicity study, pregnant rats received zidovudine up to near-lethal doses that produced peak plasma concentrations 350 times peak human plasma concentrations (300Â times the daily exposure [AUC] in humans given 600Â mg per day zidovudine). This dose was associated with marked maternal toxicity and an increased incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. However, there were no signs of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to one-fifth the lethal dose <span class="Italics">[see Nonclinical Toxicology (13.2)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d9e6f009-0d43-4ff1-bf19-d5479bff3f9b"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Because of the potential for HIV-1 transmission mothers should be instructed not to breastfeed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_dc61e3a2-7444-4b6a-871c-c2158ae60d2c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">COMBIVIR is not recommended for use in pediatric patients who weigh less than 30Â kg because it is a fixedâ€‘dose combination tablet that cannot be adjusted for this patient population <span class="Italics">[see Dosage and Administration (2.2)].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7310f210-a1f7-43a7-9998-7c28dd836ce9"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of COMBIVIR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of COMBIVIR in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d5c9735-c734-4779-a232-fbeb4288c0b8"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">COMBIVIR is not recommended for patients with creatinine clearance less than 50Â mL per min because COMBIVIR is a fixedâ€‘dose combination and the dosage of the individual components cannot be adjusted. If a dose reduction of the lamivudine or zidovudine components of COMBIVIR is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> then the individual components should be used <span class="Italics">[see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c53e427-a712-4b8b-ba94-0c98bf7c8ee3"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with Impaired Hepatic Function</h2>
<p class="First">COMBIVIR is a fixedâ€‘dose combination and the dosage of the individual components cannot be adjusted. Zidovudine is primarily eliminated by hepatic metabolism and zidovudine concentrations are increased in patients with impaired hepatic function, which may increase the risk of hematologic toxicity. Frequent monitoring of hematologic toxicities is advised.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_53ca6037-3206-44bd-a63f-7dd5ce38b2bd"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known specific treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with COMBIVIR. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored and standard supportive treatment applied as required.</p>
<p><span class="Underline">Lamivudine</span></p>
<p>Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> event.</p>
<p><span class="Underline">Zidovudine</span></p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdoses</span> of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50Â grams. No specific symptoms or signs have been identified following acute overdosage with zidovudine apart from those listed as adverse events such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and occasional reports of hematological disturbances. Patients recovered without permanent sequelae. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3â€²-azido-3â€²-deoxy-5â€²-<span class="Italics">O</span>-Î²-<span class="Italics">D</span>-glucopyranuronosylthymidine (GZDV), is enhanced.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c8639649-b38a-4381-bdef-5172799d83b5"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">COMBIVIR tablets are combination tablets containing lamivudine and zidovudine. Lamivudine (EPIVIR) and zidovudine (RETROVIR, azidothymidine, AZT, or ZDV) are synthetic nucleoside analogues with activity against HIV-1.</p>
<p>COMBIVIR tablets are for oral administration. Each film-coated tablet contains 150Â mg of lamivudine, 300Â mg of zidovudine, and the inactive ingredients colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.</p>
<p><span class="Underline">Lamivudine</span></p>
<p>The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2â€²,3â€²-dideoxy, 3â€²-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id941"></a><img alt="lamivudine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16da660b-9981-4d24-a14a-94c7744fce4f&amp;name=combivir-spl-graphic-01.jpg">
</div>
<p>Lamivudine is a white to off-white crystalline solid and is soluble in water.</p>
<p><span class="Underline">Zidovudine</span></p>
<p>The chemical name of zidovudine is 3â€²-azido-3â€²-deoxythymidine. It has a molecular formula of C<span class="Sub">10</span>H<span class="Sub">13</span>N<span class="Sub">5</span>O<span class="Sub">4</span> and a molecular weight of 267.24 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id949"></a><img alt="zidovudine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16da660b-9981-4d24-a14a-94c7744fce4f&amp;name=combivir-spl-graphic-02.jpg">
</div>
<p>Zidovudine is a white to beige, odorless, crystalline solid with a solubility of 20.1Â mg per mL in water at 25Â°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a4219bc6-018e-46ab-9298-4a267622e60c"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c16223f1-5a01-4241-9875-61c419ec09b3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">COMBIVIR is an antiretroviral agent <span class="Italics">[see Microbiology (12.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_0160d0e9-ffb7-4645-978b-1883e103b97a"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Pharmacokinetics in Adults</span></p>
<p>One COMBIVIR tablet was bioequivalent to 1 EPIVIR tablet (150Â mg) plus 1 RETROVIR tablet (300Â mg) following single-dose administration to fasting healthy subjects (nÂ =Â 24).</p>
<p><span class="Italics">Lamivudine:</span> Following oral administration, lamivudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination (approximately 5% of an oral dose after 12Â hours). In humans, the only known metabolite is the transâ€‘sulfoxide metabolite (approximately 5% of an oral dose after 12Â hours).</p>
<p><span class="Italics">Zidovudine:</span> Following oral administration, zidovudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Zidovudine is eliminated primarily by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV area under the curve (AUC) is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74% of the dose following oral administration, respectively. A second metabolite, 3â€²-amino-3â€²-deoxythymidine (AMT), has been identified in plasma. The AMT AUC was one fifth of the zidovudine AUC.</p>
<p>In humans, lamivudine and zidovudine are not significantly metabolized by cytochrome P450 enzymes.</p>
<p>The pharmacokinetic properties of lamivudine and zidovudine in fasting subjects are summarized in Table 3.</p>
<a name="_Refid_a88fe918-f924-4490-bb02-7110fef9c"></a><table width="100%">
<caption><span>Table 3. Pharmacokinetic Parameters<span class="Sup">a</span> for Lamivudine and Zidovudine in Adults</span></caption>
<col width="40%">
<col width="20%">
<col width="9%">
<col width="20%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Lamivudine</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Zidovudine</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Oral bioavailability (%)</p></td>
<td align="center" valign="top"><p class="First">86 Â± 16</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 12</p></td>
<td align="center" valign="top"><p class="First">64 Â± 10</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 5</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Apparent volume of distribution (L/kg)</p></td>
<td align="center" valign="top"><p class="First">1.3 Â± 0.4</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td align="center" valign="top"><p class="First">1.6 Â± 0.6</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 8</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Plasma protein binding (%)</p></td>
<td align="center" valign="top"><p class="First">&lt;36</p></td>
<td class="Rrule" valign="top"></td>
<td align="center" valign="top"><p class="First">&lt;38</p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">CSF:plasma ratio<span class="Sup">b</span></p></td>
<td align="center" valign="top"><p class="First">0.12 [0.04 to 0.47]</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 38<span class="Sup">c</span></p></td>
<td align="center" valign="top"><p class="First">0.60 [0.04 to 2.62]</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 39<span class="Sup">d</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Systemic clearance (L/h/kg)</p></td>
<td align="center" valign="top"><p class="First">0.33 Â± 0.06</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td align="center" valign="top"><p class="First">1.6 Â± 0.6</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Renal clearance (L/h/kg)</p></td>
<td align="center" valign="top"><p class="First">0.22Â Â±Â 0.06</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td align="center" valign="top"><p class="First">0.34 Â± 0.05</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">nÂ =Â 9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Elimination half-life (h)<span class="Sup">e</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">5 to 7</p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">0.5 to 3</p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr><td class="Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Sup">a</span> Data presented as mean Â± standard deviation except where noted.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Sup">b</span> Median [range].</p></td></tr>
<tr><td class="Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Sup">c</span> Children.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Sup">d</span> Adults.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Sup">e</span> Approximate range.</p></td></tr>
</tbody>
</table>
<p><span class="Italics">Effect of Food on Absorption of COMBIVIR: </span>COMBIVIR may be administered with or without food. The lamivudine and zidovudine AUC following administration of COMBIVIR with food was similar when compared with fasting healthy subjects (nÂ =Â 24).</p>
<p><span class="Underline">Special Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: COMBIVIR: </span>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the combination of lamivudine and zidovudine has not been evaluated (see the U.S. prescribing information for the individual lamivudine and zidovudine components).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: COMBIVIR:</span> The<span class="Italics"></span>effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the combination of lamivudine, and zidovudine has not been evaluated (see the U.S. prescribing information for the individual lamivudine and zidovudine components). </p>
<p><span class="Italics">Pregnancy: Lamivudine:</span> Lamivudine pharmacokinetics were studied in 36 pregnant women during 2Â clinical trials conducted in South Africa. Lamivudine pharmacokinetics in pregnant women were similar to those seen in non-pregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples.</p>
<p><span class="Italics">Zidovudine: </span>Zidovudine pharmacokinetics have been studied in a PhaseÂ 1 trial of 8Â women during the last trimester of pregnancy. Zidovudine pharmacokinetics were similar to those of non-pregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery.</p>
<p>Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics.</p>
<p><span class="Underline">Geriatric Patients</span></p>
<p>The pharmacokinetics of lamivudine and zidovudine have not been studied in subjects over 65Â years of age.</p>
<p><span class="Underline">Gender</span></p>
<p>There are no significant or clinically relevant gender differences in the pharmacokinetics of the individual components (lamivudine or zidovudine) based on the available information that was analyzed for each of the individual components.</p>
<p><span class="Underline">Race</span></p>
<p><span class="Italics">Lamivudine:</span> There are no significant or clinically relevant racial differences in lamivudine pharmacokinetics based on the available information that was analyzed for the individual lamivudine component.</p>
<p><span class="Italics">Zidovudine:</span> The pharmacokinetics of zidovudine with respect to race have not been determined.</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>No drug interaction trials have been conducted using COMBIVIR tablets. </p>
<p><span class="Italics">Lamivudine and Zidovudine:</span> No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12Â asymptomatic HIVâ€‘1-infected adult subjects given a single dose of zidovudine (200Â mg) in combination with multiple doses of lamivudine (300Â mg every 12Â hours). </p>
<p><span class="Underline">Other interactions</span></p>
<p><span class="Italics">Interferon Alfa: </span>There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between lamivudine and interferon alfa in a trial of 19Â healthy male subjects.</p>
<p><span class="Italics">Ribavirin: </span>InÂ vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIVâ€‘1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (nÂ =Â 18), stavudine (nÂ =Â 10), or zidovudine (nÂ =Â 6) were coadministered as part of a multi-drug regimen to HIVâ€‘1/HCV coâ€‘infected subjects <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
<p>Table 4 presents drug interaction information for the individual components of COMBIVIR.</p>
<table width="100%">
<caption><span>Table 4. Effect of Coadministered Drugs on Lamivudine and Zidovudine AUC<span class="Sup">a</span></span></caption>
<col width="24%">
<col width="20%">
<col width="4%">
<col width="10%">
<col width="17%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Coadministered Drug and Dose</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Drug and Dose</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Concentrations of Lamivudine or Zidovudine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Concentration of Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Variability</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nelfinavir</p>
<p>Â Â Â 750Â mg everyÂ 8Â h x 7 to Â Â Â 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Lamivudine</p>
<p>single 150Â mg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘10%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>1% to 20%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Trimethoprim 160Â mg/</p>
<p>Sulfamethoxazole 800Â mg Â Â Â daily x 5Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Lamivudine</p>
<p>single 300Â mg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘43%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p>32% to 55%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Atovaquone</p>
<p>Â Â Â 750Â mg every 12Â h</p>
<p>Â Â Â with food</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Zidovudine</p>
<p>200Â mg every 8Â h</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘31%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>23% to 78%<span class="Sup">b</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Clarithromycin</p>
<p>Â Â Â 500 mg twice daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 100 mg every 4 h x 7 days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“12%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>â†“34% to â†‘14%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Not Reported</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Fluconazole</p>
<p>Â Â Â 400Â mg daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 200Â mg every 8Â h</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘74%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>54% to 98%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Not Reported</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Methadone</p>
<p>Â Â Â 30 to 90Â mg daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 200Â mg every 4Â h</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘43%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>16% to 64%<span class="Sup">b</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nelfinavir</p>
<p>Â Â Â 750Â mgÂ every 8Â h x 7 to 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine single 200Â mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“35%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>28% to 41%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Probenecid </p>
<p>Â Â Â 500 mg every 6Â h x 2Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 2Â mg/kg every 8Â h x 3Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘106%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>100% to 170%<span class="Sup">b</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Rifampin</p>
<p>Â Â Â 600Â mg daily x 14 days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Zidovudine 200Â mg every 8Â h</p>
<p>x 14Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“47%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p>41% to 53%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Ritonavir</p>
<p>Â Â Â 300Â mg every 6Â h x 4Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 200 mg every 8Â h x 4Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“25%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>15% to 34%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Valproic acid </p>
<p>Â Â Â 250Â mg or 500Â mg every 8Â h x 4Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Zidovudine 100 mg every 8Â h x 4Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘80%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>64% to 130%<span class="Sup">b</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr><td class="Lrule Rrule" colspan="6" valign="top"><p class="First">â†‘ = Increase; â†“= Decrease; â†”Â =Â no significant change; AUC = area under the concentration versus time curve; CI = confidence interval.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Sup">a</span> This table is not all inclusive.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Sup">b</span> Estimated range of percent difference.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7362b8b-72cb-4084-a1e4-461cd5fd59ce"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p><span class="Italics">Lamivudine: </span>Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5â€²-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5â€²-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue.</p>
<p><span class="Underline">Antiviral Activity</span></p>
<p><span class="Italics">Lamivudine plus Zidovudine:</span> In HIV-1â€“infected MTâ€‘4 cells, lamivudine in combination with zidovudine at various ratios exhibited synergistic antiretroviral activity.</p>
<p><span class="Italics">Lamivudine:</span> The antiviral activity of lamivudine against HIVâ€‘1 was assessed in a number of cell lines including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> (PBMCs) using standard susceptibility assays. EC<span class="Sub">50</span> values were in the range of 0.003 to 15Â microM (1Â microMÂ =Â 0.23Â mcg per mL). The median EC<span class="Sub">50</span> values of lamivudine were 60Â nM (range: 20 to 70Â nM), 35Â nM (range: 30 to 40Â nM), 30Â nM (range: 20 to 90Â nM), 20Â nM (range: 3 to 40Â nM), 30Â nM (range: 1 to 60 nM), 30Â nM (range: 20 to 70Â nM), 30Â nM (range: 3 to 70Â nM), and 30Â nM (range: 20 to 90Â nM) against HIVâ€‘1 clades A-G and group O viruses (nÂ =Â 3 except nÂ =Â 2 for clade B) respectively. The EC<span class="Sub">50</span> values against HIVâ€‘2 isolates (nÂ =Â 4) ranged from 0.003 to 0.120Â microM in PBMCs. Ribavirin (50Â microM) used in the treatment of chronic HCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> decreased the anti-HIVâ€‘1 activity of lamivudine by 3.5â€‘fold in MTâ€‘4 cells.</p>
<p><span class="Italics">Zidovudine:</span> The antiviral activity of zidovudine against HIVâ€‘1 was assessed in a number of cell lines including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The EC<span class="Sub">50</span> and EC<span class="Sub">90</span> values for zidovudine were 0.01 to 0.49Â microM (1Â microMÂ =Â 0.27Â mcg per mL) and 0.1 to 9Â microM, respectively. HIVâ€‘1 from therapyâ€‘naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.011Â microM (range: 0.005 to 0.110Â microM) from Virco (nÂ =Â 92 baseline samples) and 0.0017Â microM (range: 0.006 to 0.0340Â microM) from Monogram Biosciences (nÂ =Â 135 baseline samples). The EC<span class="Sub">50</span> values of zidovudine against different HIVâ€‘1 clades (A-G) ranged from 0.00018 to 0.02Â microM, and against HIVâ€‘2 isolates from 0.00049 to 0.004Â microM. Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture.</p>
<p>Neither lamivudine nor zidovudine were antagonistic to tested anti-HIV agents, with the exception of stavudine where an antagonistic relationship with zidovudine has been demonstrated in cell culture. See full prescribing information for EPIVIR (lamivudine) and RETROVIR (zidovudine). </p>
<p><span class="Underline">Resistance</span></p>
<p>In subjects receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIVâ€‘1 isolates from most subjects became phenotypically and genotypically resistant to lamivudine within 12Â weeks. </p>
<p>HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to both lamivudine and zidovudine have been isolated from subjects after prolonged lamivudine/zidovudine therapy. Dual resistance required the presence of multiple amino acid substitutions, the most essential of which may be G333E. The incidence of dual resistance and the duration of combination therapy required before dual resistance occurs are unknown.</p>
<p><span class="Italics">Lamivudine:</span> Lamivudineâ€‘resistant isolates of HIVâ€‘1 have been selected in cell culture and have also been recovered from subjects treated with lamivudine or lamivudine plus zidovudine. Genotypic analysis of isolates selected in cell culture and recovered from lamivudineâ€‘treated subjects showed that the resistance was due to a specific amino acid substitution in the HIVâ€‘1 reverse transcriptase at codonÂ 184 changing the methionine to either isoleucine or valine (M184V/I).</p>
<p><span class="Italics">Zidovudine:</span> HIVâ€‘1 isolates with reduced susceptibility to zidovudine have been selected in cell culture and were also recovered from subjects treated with zidovudine. Genotypic analyses of the isolates selected in cell culture and recovered from zidovudineâ€‘treated subjects showed thymidine analog mutation (TAM) substitutions in HIVâ€‘1 RT (M41L, D67N, K70R, L210W, T215Y or F, and K219E/R/H/Q/N) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of substitutions. </p>
<p>In some subjects harboring zidovudineâ€‘resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12Â weeks of treatment with lamivudine and zidovudine. </p>
<p><span class="Underline">Crossâ€‘resistance</span></p>
<p>Crossâ€‘resistance has been observed among NRTIs. Crossâ€‘resistance between lamivudine and zidovudine has not been reported. In some subjects treated with lamivudine alone or in combination with zidovudine, isolates have emerged with a substitution at codonÂ 184, which confers resistance to lamivudine. </p>
<p>TAM substitutions are selected by zidovudine and confer crossâ€‘resistance to abacavir, didanosine, stavudine, and tenofovir.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_68921e12-8509-440c-bc73-beccb0c9e64d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_cd4676de-6847-4127-b0fa-5dd6449a9655"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenicity</span></p>
<p><span class="Italics">Lamivudine:</span> Longâ€‘term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10Â times (mice) and 58Â times (rats) the human exposures at the recommended dose of 300Â mg.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine was administered orally at 3Â dosage levels to separate groups of mice and rats (60Â females and 60Â males in each group). Initial single daily doses were 30, 60, and 120Â mg per kg per day in mice and 80, 220, and 600Â mg per kg per day in rats. The doses in mice were reduced to 20, 30, and 40Â mg per kg per day after dayÂ 90 because of treatmentâ€‘related <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, whereas in rats only the high dose was reduced to 450Â mg per kg per day on dayÂ 91 and then to 300Â mg per kg per day on dayÂ 279.</p>
<p>In mice, 7Â lateâ€‘appearing (after 19Â months) vaginal neoplasms (5Â nonmetastasizing squamous cell carcinomas, 1Â squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, and 1Â squamous <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>) occurred in animals given the highest dose. One lateâ€‘appearing squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.</p>
<p>In rats, 2Â lateâ€‘appearing (after 20Â months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drugâ€‘related tumors were observed in either sex of either species.</p>
<p>At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3Â times (mouse) and 24Â times (rat) the estimated human exposure at the recommended therapeutic dose of 100Â mg every 4Â hours.</p>
<p>It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Underline">Mutagenicity</span></p>
<p><span class="Italics">Lamivudine: </span>Lamivudine was mutagenic in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Lamivudine was not mutagenic in a microbial mutagenicity assay, in an inÂ vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine was mutagenic in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, positive in an inÂ vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p><span class="Italics">Lamivudine:</span> Lamivudine did not affect male or female fertility in rats at a dose associated with exposures approximately 130Â times higher than the exposure in humans at the dose of 300Â mg.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine, administered to male and female rats at doses up to 7Â times the usual adult dose based on body surface area considerations, had no effect on fertility judged by conception rates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ecbfa92-dbda-4b86-862d-ffe9024aa285"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Underline">Lamivudine</span></p>
<p>Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000Â mg per kg per day and 1,000Â mg per kg per day, respectively, producing plasma levels up to approximately 35Â times that for the adult HIV dose. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 35Â times those in humans. Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.</p>
<p><span class="Underline">Zidovudine</span></p>
<p>Oral teratology studies in the rat and in the rabbit at doses up to 500Â mg per kg per day revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450Â mg per kg per day and rabbits given 500Â mg per kg per day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one-half of the daily dose) in rats 66 to 226Â times, and in rabbits 12 to 87Â times, mean steadyâ€‘state peak human plasma concentrations (after one-sixth of the daily dose) achieved with the recommended daily dose (100Â mg every 4Â hours). In an inÂ vitro experiment with fertilized mouse oocytes, zidovudine exposure resulted in a doseâ€‘dependent reduction in blastocyst formation. In an additional teratology study in rats, a dose of 3,000Â mg per kg per day (very near the oral median lethal dose in rats of 3,683Â mg per kg) caused marked maternal toxicity and an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. This dose resulted in peak zidovudine plasma concentrations 350Â times peak human plasma concentrations. (Estimated AUC in rats at this dose level was 300Â times the daily AUC in humans given 600Â mg per day.) No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in this experiment at doses of 600Â mg per kg per day or less.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_814c8d07-fd70-415a-b2ec-2045cca8130e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">One COMBIVIR tablet given twice daily is an alternative regimen to EPIVIR tablets 150Â mg twice daily plus RETROVIR 600Â mg per day in divided doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b89d5035-c3d3-4b24-b701-5292b3502fc5"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adults</h2>
<p class="First">The NUCB3007 (CAESAR) trial was conducted using EPIVIR 150â€‘mg tablets (150Â mg twice daily) and RETROVIR 100â€‘mg capsules (2 x 100Â mg 3 times daily). CAESAR was a multiâ€‘center, double-blind, placebo-controlled trial comparing continued current therapy (zidovudine alone [62% of subjects] or zidovudine with didanosine or zalcitabine [38% of subjects]) to the addition of EPIVIR or EPIVIR plus an investigational non-nucleoside reverse transcriptase inhibitor, randomized 1:2:1. A total of 1,816Â HIVâ€‘1â€‘infected adults with 25 to 250 (median 122) CD4Â cells per mm<span class="Sup">3</span> at baseline were enrolled: median age was 36Â years, 87% were male, 84% were nucleoside-experienced, and 16% were therapyâ€‘naive. The median duration on trial was 12Â months. Results are summarized in TableÂ 5.</p>
<a name="_Refid_d83ea1bf-769c-43a1-9bd2-f79a7ea08"></a><table width="100%">
<caption><span>Table 5. Number of Subjects (%) with at Least 1 HIV-1 Disease-progression Event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></caption>
<col width="24%">
<col width="25%">
<col width="21%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Endpoint</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Current Therapy (nÂ =Â 460)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">EPIVIR</span></p>
<p><span class="Bold">plus Current Therapy</span></p>
<p><span class="Bold">(nÂ =Â 896)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">EPIVIR</span></p>
<p><span class="Bold">plus a NNRTI<span class="Sup">a</span></span></p>
<p><span class="Bold">plus Current Therapy (nÂ =Â 460)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">HIV-1 progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">90 (19.6%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">86 (9.6%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">41 (8.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">27 (5.9%)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">23 (2.6%)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14 (3.0%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Sup">a</span> An investigational non-nucleoside reverse transcriptase inhibitor not approved in the United States.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcfb408a-539e-4184-b42c-b41d07b38a16"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Prevention of Maternal-Fetal HIV-1 Transmission</h2>
<p class="First">The utility of zidovudine alone for the prevention of maternal-fetal HIV-1 transmission was demonstrated in a randomized, double-blind, placebo-controlled trial conducted in HIV-1-infected pregnant women with CD4+ cell counts of 200 to 1,818Â cells per mm<span class="Sup">3</span> (median in the treated group: 560Â cells per mm<span class="Sup">3</span>) who had little or no previous exposure to zidovudine. Oral zidovudine was initiated between 14 and 34Â weeks of gestation (median 11Â weeks of therapy) followed by IV administration of zidovudine during labor and delivery. Following birth, neonates received oral zidovudine syrup for 6Â weeks. The trial showed a statistically significant difference in the incidence of HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in the neonates (based on viral culture from peripheral blood) between the group receiving zidovudine and the group receiving placebo. Of 363Â neonates evaluated in the trial, the estimated risk of HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was 7.8% in the group receiving zidovudine and 24.9% in the placebo group, a relative reduction in transmission risk of 68.7%. Zidovudine was well tolerated by mothers and infants. There was no difference in pregnancy-related adverse events between the treatment groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f6edcb3e-c4eb-4e71-9896-9568dedfab10"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">COMBIVIR tablets, containing 150Â mg lamivudine and 300Â mg zidovudine, are white, scored, film-coated, modified-capsule-shaped tablets, debossed on both tablet faces, such that when broken in half, the full â€œGXFC3â€? code is present on both halves of the tablet (â€œGXâ€? on one face and â€œFC3â€? on the opposite face of the tablet). They are available as follows:</p>
<dl>
<dt>Â </dt>
<dd>60 Tablets/Bottle	(NDC 49702-202-18).</dd>
<dt>Â </dt>
<dd>Unit Dose Pack of 120	(NDC 49702-202-29).</dd>
</dl>
<p><span class="Bold">Store between 2Â° and 30Â°C (36Â° and 86Â°F).</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_db717905-9942-4590-b7a9-1eddc8daeb3d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></p>
<p>Inform patients that the important toxicities associated with zidovudine are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Inform them of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced HIVâ€‘1 disease <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes, similar to that produced by HIVâ€‘1 disease, have been associated with prolonged use of zidovudine <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span></p>
<p>Inform patients that some HIV medicines, including COMBIVIR, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
<p><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Advise patients coâ€‘infected with HIVâ€‘1 and HBV that worsening of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Advise patients to discuss any changes in regimen with their physician <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p>Inform patients with HIVâ€‘1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that hepatic decompensation (some fatal) has occurred in HIVâ€‘1/HCV co-infected patients receiving combination antiretroviral therapy for HIVâ€‘1 and interferon alfa with or without ribavirin <span class="Italics">[see Warnings and Precautions (5.6)].</span></p>
<p><span class="Underline">Related Products that are Not Recommended</span></p>
<p>Inform patients that they should not take COMBIVIR with ATRIPLA<span class="Sup">Â®</span>, COMPLERA<span class="Sup">Â®</span>, DUTREBIS<span class="Sup">â„¢</span>, EMTRIVA<span class="Sup">Â®</span>, EPIVIR, EPIVIR-HBV<span class="Sup">Â®</span>, EPZICOM<span class="Sup">Â®</span>, RETROVIR, STRIBILD<span class="Sup">Â®</span>, TRIUMEQ<span class="Sup">Â®</span>, TRIZIVIR<span class="Sup">Â®</span>, or TRUVADA<span class="Sup">Â®</span><span class="Italics">[see Warnings and Precautions (5.5)]. </span></p>
<p><span class="Underline">Drug Interactions</span></p>
<p>Caution patients about the use of other medications, including ganciclovir, interferon alfa, and ribavirin, which may exacerbate the toxicity of zidovudine <span class="Italics">[see Drug Interactions (7.3)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></span></p>
<p>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.8)].</span></p>
<p><span class="Underline">Redistribution/Accumulation of Body Fat</span></p>
<p>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</p>
<p><span class="Underline">Information about HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p>COMBIVIR is not a cure for HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients must remain on continuous HIV therapy to control HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illness. Inform patients that sustained decreases in plasma HIVâ€‘1 RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>Advise patients to remain under the care of a physician when using COMBIVIR.</p>
<p>Advise patients to take all HIV medications exactly as prescribed.</p>
<p>Advise patients to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<p>Advise patients not to re-use or share needles or other injection equipment.</p>
<p>Advise patients not to share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</p>
<p>Advise patients to always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</p>
<p>Female patients should be advised not to breastfeed. Mothers with HIVâ€‘1 should not breastfeed because HIVâ€‘1 can be passed to the baby in the breast milk.</p>
<p>Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is time for the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.</p>
<p>EPIVIR, RETROVIR, EPZICOM, TRIUMEQ, and TRIZIVIR are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare<br>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from<br><span class="Bold">Shire Pharmaceuticals Group plc</span><br>Basingstoke, UK</p>
<p>Â©2015 the ViiV Healthcare group of companies. All rights reserved.</p>
<p>CMB: 6PI</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8127624a-c0c8-49ec-8f0b-b94e20bb6998"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 49702-202-18 </span></p>
<p><span class="Bold">COMBIVIR<span class="Sup">Â®</span></span></p>
<p><span class="Bold"><span class="Italics">(lamivudine and zidovudine)</span></span></p>
<p><span class="Bold"><span class="Italics">Tablets 150 mg/300 mg</span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p>Each tablet contains 150 mg of lamivudine and 300 mg of zidovudine.</p>
<p>Store between 2<span class="Sup">o</span> and 30<span class="Sup">o</span>C (36<span class="Sup">o</span> and 86<span class="Sup">o</span>F).</p>
<p>See prescribing information for dosage information.</p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Made in UK</p>
<p>10000000082963 Rev. 8/10</p>
<div class="Figure">
<a name="id1536"></a><img alt="COMBIVIR label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16da660b-9981-4d24-a14a-94c7744fce4f&amp;name=combivir-spl-graphic-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMBIVIRÂ 		
					</strong><br><span class="contentTableReg">lamivudine and zidovudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49702-202</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">150Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ZIDOVUDINE</strong> (ZIDOVUDINE) </td>
<td class="formItem">ZIDOVUDINE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (modified-capsule-shaped tablets) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GXFC3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49702-202-18</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">10/19/2010</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49702-202-29</td>
<td class="formItem">120  in 1 DOSE PACK; Combination Product Type = C112160</td>
<td class="formItem">10/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020857</td>
<td class="formItem">10/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ViiV Healthcare Company
							(027295585)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c9013d1c-2576-4d28-b76e-097efaa2b72e</div>
<div>Set id: 16da660b-9981-4d24-a14a-94c7744fce4f</div>
<div>Version: 9</div>
<div>Effective Time: 20150928</div>
</div>
</div>Â <div class="DistributorName">ViiV Healthcare Company</div></p>
</body></html>
